News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Subcutaneous vs Intravenous Trastuzumab/Pertuzumab in HER2+ Breast Cancer
Jul 25, 2024, 20:48

Subcutaneous vs Intravenous Trastuzumab/Pertuzumab in HER2+ Breast Cancer

Dana-Farber’s Breast Oncology Center shared on X:

“New in JCO Oncology Practice:

Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial).

Full Text here.”

Source: Dana-Farber’s Breast Oncology Center/X

Breast Cancer

Authors: Adrienne G Waks, Emily L Chen, Noah Graham, Anna Mae Frey, Kenneth Almeida, Victoria Attaya, Cari Ryding, Ibrahim Abbass, Anita Fung, Jesse Sussell, Patricia Cortazar, Caroline Harvey, Denise Leth, Meredith Faggen, Natalie Sinclair, Jeanna Walsh, Nadine Tung, Sarah Sinclair, Steve Lo, Denise Yardley, Vicente Valero, Jane Meisel, Tarah J Ballinger, Sylvia Adams, Lisa A Carey, Julia K Rauch, Vandana G Abramson, Nicole O Williams, Wendy Y Chen, Jose P Leone, Susan T Schumer, Nabihah Tayob, Sara M Tolaney

Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial)

Anita Fung Anna Mae Frey Breast Cancer cancer Cari Ryding Caroline Harvey Dana-Farber’s Breast Oncology Center Denise Leth Denise Yardley Emily L Chen Here are the names with the numbers removed: Adrienne G Waks Ibrahim Abbass Jane Meisel JCO Oncology Practice Jeanna Walsh Jesse Sussell Jose P Leone Julia K Rauch Kenneth Almeida Lisa A. Carey Meredith Faggen Nabihah Tayob Nadine Tung Natalie Sinclair Nicole O Williams Noah Graham OncoDaily Oncology Patricia Cortazar pertuzumab Sara M. Tolaney Sarah Sinclair Steve Lo Susan T Schumer Sylvia Adams Tarah J Ballinger trastuzumab Vandana G Abramson Vicente Valero Victoria Attaya Wendy Y. Chen
Special Coverage
Blog
Dec 21, 2024, 14:06
The Accelerate 2025 Annual Conference Agenda Is Here!
Blog
Dec 21, 2024, 14:03
Pioneer the future of discovery and innovation with a fully funded Bicentenary PhD Studentship at The University of Manchester
Blog
Dec 21, 2024, 14:00
NCI Division of Cancer Prevention - DHT Derived Biomarkers and COAs for Remote Monitoring and Endpoint Development
Blog
Dec 21, 2024, 13:51
The ESMO President Letter emphasises the importance of collective action to shape the future of oncology
Blog
Dec 21, 2024, 13:48
Overcoming recurrence: How research is bringing new hope for breast cancer patients - The Institute of Cancer Research
Blog
Dec 21, 2024, 13:46
IARC - Cancer Incidence in Five Continents, Vol XII
Blog
Dec 21, 2024, 13:43
National University Cancer Institute, Singapore clinicians had the exciting opportunity to present their work at the ESMO Asia 2024
Blog
Dec 21, 2024, 13:40
UICC - Welcoming the newest member, The World Hepatitis Alliance
Blog
Dec 21, 2024, 13:35
Pediatric Cancer and Blood Disorders Center of Armenia - Prioritizing the continuous education and knowledge exchange of the medical staff
Blog
Dec 21, 2024, 13:33
SIOP Europe - International Childhood Cancer Day 2025
Blog
Dec 21, 2024, 13:29
Canadian Cancer Society - How 5 organizations are working to take on cancer’s biggest issues
Radiotherapy
Dec 21, 2024, 13:20
What Is Flash Radiotherapy and How It Works? Pros and Cons